コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 resent in both the high salt-extractable and RIPA-resistant, SDS-extractable fraction in young human
8 ry test, few studies are available comparing RIPA to commercially available serologic test methods.
9 en compared with several other test formats, RIPA demonstrated equivalent or superior rates of agreem
10 rted that the pathway of IRF-3 activation in RIPA was independent of and distinct from the known path
11 ls treated for 5 to 60 minutes were lysed in RIPA buffer and subjected to Western blot with phospho (
12 en the activated T-lymphocytes were lysed in RIPA buffer containing anti-GraB, no proteolytic process
13 eal and conjunctival epithelia were lysed in RIPA buffer for Western blot with MAPK antibodies, or th
14 ls treated for 5 to 60 minutes were lysed in RIPA buffer for Western blot with phospho-specific antib
16 noprecipitated in vitro translated P well in RIPA, but three immunoprecipitated P poorly in IPP150.
17 A detected antibodies in 38.1% (16 of 42) of RIPA-negative patients with MG with 100% specificity.
21 of protection against disease and show that RIPA is most sensitive for detection of early vaccine-in
23 considerably among the tests, with only the RIPA and the Organon and Gull assays identifying reactiv
24 ed in vitro, and lysates were prepared using RIPA buffer which contains 1% Nonidet P-40, 0.5% deoxych
25 use, which expressed a mutant IRF-3 that was RIPA-competent but transcriptionally inert; this single-
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。